Uncover key drivers, emerging technologies, and competitive movements shaping the fatty acid oxidation disorders (faods) market from 2026–2035 with trusted insights from The Business Research Company
Across 2026–2030, what is the expected market valuation path of the Fatty Acid Oxidation Disorders (FAODs) Market?
The market size for fatty acid oxidation disorders (faods) has experienced substantial growth in recent years. It is anticipated to increase from $10.23 billion in 2025 to $11.01 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. The historical expansion of this market can be attributed to the introduction of neonatal screening initiatives, a greater incidence of inherited metabolic disorder diagnoses, heightened clinical awareness, the proliferation of hospital-based metabolic clinics, and the accessibility of supportive drug therapies.
The market for fatty acid oxidation disorders (FAODs) is projected to experience substantial expansion in the coming years, with its valuation anticipated to reach $14.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.5%. This anticipated increase during the forecast period stems from developments in enzyme replacement therapies, broader genetic research efforts, the proliferation of personalized nutrition strategies, more favorable reimbursement policies for rare diseases, and greater governmental backing for early detection programs. Key patterns expected during this timeframe involve the increasing uptake of newborn screening initiatives, a heightened emphasis on diagnosing metabolic disorders promptly, the expanding application of nutritional and dietary interventions, greater awareness regarding rare disease treatments, and enhanced availability of therapies for metabolic disorders.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21964&type=smp
Which Drivers Are Supporting The Rise Of The Fatty Acid Oxidation Disorders (FAODs) Market?
The increasing demand for gene therapy is anticipated to drive the growth of the fatty acid oxidation disorders (FAODs) market. Gene therapy is a medical technique that involves modifying or replacing defective genes to treat or prevent diseases. The rising demand for gene therapy is due to its potential to address genetic disorders, cancer, and rare diseases by targeting their underlying genetic causes, which has led to significant investments and advancements in biotechnology. Gene therapy aims to correct metabolic deficiencies caused by fatty acid oxidation disorders by delivering functional genes, restoring enzymatic activity, enhancing energy production, and preventing disease complications. For instance, in 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based, nonprofit, professional medical and scientific organization, reports that the global pipeline of gene, cell, and RNA therapies rose from 3,483 in Q4 2022 to 3,951 in Q4 2023, reaching 4,238 in Q4 2024. Therefore, the increasing demand for gene therapy is fueling the expansion of the fatty acid oxidation disorders (FAODs) market.
What Leading Segments Are Studied In The Fatty Acid Oxidation Disorders (FAODs) Market?
The fatty acid oxidation disorders (faods) market covered in this report is segmented –
1) By Type: Long Chain, Short Chain
2) By Drug Type: Levocarnitine, Dextrose, Riboflavin, Other Drug Types
3) By Route of Administration: Oral, Intravenous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Stores
5) By End User: Hospitals, Clinics, Pharmaceutical Companies
Subsegments:
1) By Long Chain: Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD), Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD), Trifunctional Protein Deficiency (TFP), Carnitine Palmitoyltransferase II Deficiency (CPT II)
2) By Short Chain: Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD), Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD), Carnitine Uptake Defect (CUD)
What Industry Trends Are Transforming The Fatty Acid Oxidation Disorders (FAODs) Market?
Key companies operating in the fatty acid oxidation disorders (FAODs) market are prioritizing the development of innovative solutions, such as peroxisome proliferator-activated receptor delta (PPARδ) agonists, to enhance metabolic control and improve outcomes for patients with FAODs. A peroxisome proliferator-activated receptor delta (PPARδ) agonist is a substance that activates the PPARδ receptor, which plays a role in regulating lipid metabolism, inflammation, and energy balance, potentially offering therapeutic advantages for metabolic and cardiovascular diseases. For instance, in January 2023, Reneo Pharmaceuticals Inc., a US-based clinical-stage pharmaceutical company, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its investigative drug, Mavodelpar (REN001). This drug targets long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, a genotype associated with long-chain fatty acid oxidation disorder (LC-FAOD). By activating PPARδ, mavodelpar aims to improve mitochondrial function, optimize energy metabolism, and mitigate symptoms linked to LC-FAOD.
Which Major Industry Participants Are Leading The Fatty Acid Oxidation Disorders (FAODs) Market Growth?
Major companies operating in the fatty acid oxidation disorders (faods) market are Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc, Sanofi SA, Novo Nordisk A S, Pfizer Inc, Merck & Co Inc, AstraZeneca PLC, Amgen Inc, AbbVie Inc, BioMarin Pharmaceutical Inc, PTC Therapeutics Inc, Horizon Therapeutics PLC, Recordati Rare Diseases SpA, Orphazyme A S, Mitsubishi Tanabe Pharma Corporation, Alexion Pharmaceuticals Inc (AstraZeneca Rare Disease), REGENXBIO Inc, Avrobio Inc, Homology Medicines Inc, Abeona Therapeutics Inc
Access The Complete Report For Deeper Market Insights:
Which Region Is Projected To Lead The Fatty Acid Oxidation Disorders (FAODs) Market During The Forecast Period?
Asia-Pacific was the largest region in the fatty acid oxidation disorders (FAODs) market in 2025. The regions covered in the fatty acid oxidation disorders (faods) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Fatty Acid Oxidation Disorders (FAODs) Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21964&type=smp
Browse Through More Reports Similar to the Global Fatty Acid Oxidation Disorders (FAODs) Market 2026, By The Business Research Company
Palm Kernel Fatty Acids Market Report 2026
https://www.thebusinessresearchcompany.com/report/palm-kernel-fatty-acids-global-market-report
Tall Oil Fatty Acid Market Report 2026
https://www.thebusinessresearchcompany.com/report/tall-oil-fatty-acid-global-market-report
Fats And Oils Market Report 2026
https://www.thebusinessresearchcompany.com/report/fats-and-oils-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model